Characteristic | Total | No known HIV infection | HIV diagnosed | ||||||
---|---|---|---|---|---|---|---|---|---|
n = 840 | n = 821 | n = 19 | |||||||
Hepatitis C prevalence | % | (95%-CI) | n | % | (95%-CI) | n | % | (95%-CI) | n |
Antibody* | 0.8 | (0.4-1.7) | 7 | 0.4 | (0.12-1.1) | 3 | 21.1 | (8.5-43.3) | 4 |
Antigen* | 0.2 | (0.1-0.9) | 2 | 0.1 | (0.02-0.7) | 1 | 5.3 | (0.9-24.6) | 1 |
Age | Years | Years | Years | ||||||
Range | 17-79 | 17-79 | 19-59 | ||||||
25%-, 50%-, 75%-quartiles | 26, 33, 41 | 26, 33, 41 | 33, 38, 47 | ||||||
Country of origin | % | (95%-CI 1 ) | n | % | (95%-CI) | n | % | (95%-CI) | n |
By nationality | |||||||||
Swiss | 70.4 | (67.2-73.3) | 591 | 70.6 | (67.4-73.6) | 580 | 57.9 | (36.3-76.9) | 11 |
Non-Swiss | 21.2 | (18.6-24.1) | 178 | 21.0 | (18.3-23.9) | 172 | 31.6 | (15.4-54.0) | 6 |
Unknown | 8.5 | (6.8-10.5) | 71 | 8.4 | (6.7-10.5) | 69 | 10.5 | (2.9-31.4) | 2 |
By national HCV prevalence2 | |||||||||
< 1.5% | 3.5 | (2.4-4.9) | 29 | 3.3 | (2.3-4.7) | 27 | 10.5 | (2.9-31.4) | 2 |
1.5-3.5% (incl. Switzerland) | 87.0 | (84.6-89.1) | 731 | 87.3 | (84.9-89.4) | 717 | 73.7 | (51.2-88.2) | 14 |
> 3.5% | 1.1 | (0.6-2.0) | 9 | 1.0 | (0.5-1.9) | 8 | 5.3 | (0.9-24.6) | 1 |
Unknown | 8.5 | (6.8-10.5) | 71 | 8.4 | (6.7-10.5) | 69 | 10.5 | (2.9-31.4) | 2 |
Blood exposures | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n |
Blood transfusion before 1985 | 1.3 | (0.7-2.4) | 11 | 1.4 | (0.8-2.4) | 11 | 0.0 | (0.0-16.8) | 0 |
Piercing | 24.7 | (21.8-27.8) | 198 | 24.5 | (21.6-27.7) | 192 | 31.6 | (15.4-54.0) | 6 |
Performed abroad | 6.1 | (4.6-7.9) | 51 | 6.0 | (4.5-7.8) | 49 | 10.5 | (2.9-31.4) | 2 |
Genital piercing | 2.8 | (1.8-4.2) | 22 | 2.7 | (1.8-4.1) | 21 | 6.2 | (1.1-28.3) | 1 |
Tattoo | 19.9 | (17.2-23.0) | 145 | 19.6 | (16.8-22.7) | 139 | 35.3 | (17.3-58.7) | 6 |
Performed abroad | 7.9 | (6.2-9.9) | 66 | 7.7 | (6.0-9.7) | 63 | 15.8 | (5.5-37.6) | 3 |
Current drug use | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n |
IDU3 | 3.3 | (2.2-5.0) | 22 | 3.1 | (2.0-4.7) | 20 | 13.3 | (3.7-37.9) | 2 |
NIDU of cocaine / amph.4* | 13.6 | (11.3-16.3) | 99 | 12.8 | (10.6-15.5) | 91 | 47.0 | (26.2-69.0) | 8 |
Ecstasy* | 12.2 | (10.0-14.8) | 87 | 11.8 | (9.6-14.4) | 82 | 31.3 | (14.2-55.6) | 5 |
Cannabis* | 20.4 | (17.6-23.4) | 151 | 19.8 | (17.1-22.9) | 144 | 46.7 | (24.8-69.9) | 7 |
Any of the above* | 50.0 | (46.6-53.4) | 412 | 48.9 | (45.5-52.4) | 394 | 94.7 | (75.4-99.1) | 18 |
(Continued) | Total | No known HIV infection | HIV diagnosed | ||||||
n = 840 | n = 821 | n = 19 | |||||||
Sexual partners last year | Number | Number | Number | ||||||
Range | 0-500 | 0-500 | 0-200 | ||||||
25%-, 50%-, 75%-quartiles | 4, 6, 15 | 4, 6, 12 | 10, 20, 50 | ||||||
Valid% | (95%-CI) | n | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n | |
More than 10 sexual partners* | 30.1 | (27.1-33.3) | 250 | 29.2 | (26.2-32.4) | 237 | 68.4 | (46.0-84.6) | 13 |
UAI 5 partners last year | Number | Number | Number | ||||||
Range | 0-200 | 0-60 | 0-200 | ||||||
25%-, 50%-, 75%-quartiles | 0, 1, 1 | 0, 1, 1 | 0, 1, 6 | ||||||
Valid% | (95%-CI) | n | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n | |
More than 10 UAI partners* | 1.1 | (0.6-2.0) | 9 | 0.6 | (0.3-1.4) | 5 | 21.1 | (8.5-43.3) | 4 |
UAI episodes last year | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n |
With steady partner* | 48.5 | (45.1-52.0) | 384 | 49.1 | (45.6-52.6) | 380 | 23.5 | (9.6-47.2) | 4 |
With known casual partners | 25.1 | (22.2-28.2) | 201 | 24.9 | (22.0-28.1) | 195 | 33.3 | (16.3-56.3) | 6 |
With anonymous partners* | 11.8 | (9.7-14.3) | 92 | 11.3 | (9.3-13.8) | 86 | 31.6 | (15.4-54.0) | 6 |
“Hard” sexual practices* 6 | |||||||||
Any that might lead to bleeding | 12.1 | (10.1-14.5) | 102 | 11.7 | (9.7-14.1) | 96 | 31.6 | (15.4-54.0) | 6 |
Fisting, receptive* | 4.0 | (2.9-5.6) | 34 | 3.8 | (2.7-5.3) | 31 | 15.8 | (5.5-37.6) | 3 |
Dildo usage, receptive | 6.9 | (5.4-8.8) | 58 | 6.7 | (5.2-8.6) | 55 | 15.8 | (5.5-37.6) | 3 |
Anal dilatation, receptive | 2.3 | (1.5-3.5) | 19 | 2.1 | (1.3-3.3) | 17 | 10.5 | (2.9-31.4) | 2 |
Enema, receptive | 1.2 | (0.6-2.2) | 10 | 1.1 | (0.6-2.1) | 9 | 5.3 | (0.9-24.7) | 1 |
Catheterisation, receptive | 1.2 | (0.6-2.2) | 10 | 1.2 | (0.6-2.2) | 10 | 0.0 | (0.0-16.8) | 0 |
With steady partner | 6.9 | (5.3-8.8) | 57 | 6.7 | (5.2-8.6) | 54 | 15.8 | (5.5-37.6) | 3 |
With known casual partners | 11.3 | (9.3-13.6) | 94 | 10.9 | (8.9-13.2) | 89 | 26.3 | (11.8-48.8) | 5 |
With anonymous partners* | 5.9 | (4.5-7.7) | 49 | 5.5 | (4.2-7.3) | 45 | 21.1 | (8.5-43.3) | 4 |
At home | 12.6 | (10.6-15.1) | 105 | 12.3 | (10.2-14.7) | 100 | 26.4 | (11.9-48.9) | 5 |
At private sex parties* | 4.6 | (3.4-6.3) | 38 | 4.2 | (3.0-5.8) | 34 | 21.1 | (8.5-43.4) | 4 |
In sex clubs* | 6.9 | (5.4-8.8) | 57 | 6.3 | (4.8-8.2) | 51 | 31.6 | (15.4-54.0) | 6 |
In cruising areas* | 3.4 | (2.4-4.9) | 28 | 3.1 | (2.1-4.5) | 25 | 15.8 | (5.5-37.6) | 3 |
Group sex7* | 5.4 | (4.0-7.1) | 45 | 4.9 | (3.6-6.6) | 40 | 26.3 | (11.8-48.8) | 5 |
Lifetime history of STIs 8 | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n | Valid% | (95%-CI) | n |
Urethral gonorrhea* | 20.2 | (17.6-23.1) | 168 | 19.6 | (17.0-22.5) | 159 | 47.4 | (27.4-68.3) | 9 |
Rectal gonorrhea | 1.7 | (1.0-2.8) | 14 | 1.6 | (0.9-2.7) | 13 | 5.3 | (0.9-24.7) | 1 |
Pharyngeal gonorrhea | 1.5 | (0.9-2.6) | 13 | 1.6 | (0.9-2.7) | 13 | 0.0 | (0.0-16.8) | 0 |
Chlamydial infection* | 10.9 | (9.0-13.2) | 91 | 10.5 | (8.6-12.8) | 85 | 31.6 | (15.4-54.0) | 6 |
Syphilis* | 8.1 | (6.4-10.1) | 68 | 7.1 | (5.5-9.1) | 58 | 52.6 | (31.7-72.6) | 10 |
Hepatitis A | 2.2 | (1.4-3.4) | 18 | 2.0 | (1.2-3.2) | 16 | 10.5 | (2.9-31.4) | 2 |
Hepatitis B* | 2.3 | (1.5-3.5) | 19 | 1.8 | (1.1-3.0) | 15 | 21.1 | (8.5-43.4) | 4 |
Genital herpes | 2.5 | (1.6-3.8) | 21 | 2.4 | (1.6-3.7) | 20 | 5.3 | (0.9-24.7) | 1 |
Genital or anal warts* | 7.8 | (6.2-9.8) | 65 | 7.2 | (5.6-9.2) | 59 | 31.6 | (15.4-54.0) | 6 |
Lesion-prone STIs9 * | 18.2 | (15.8-21.0) | 153 | 17.2 | (14.7-19.9) | 141 | 63.2 | (41.1-80.9) | 12 |